Method miniaturization, traditionally valued by analytical scientists for faster separations, reduced solvent use, and sometimes improved sensitivity, is now being recast as a vital climate strategy. The latest Carbon Impact of Biotech & Pharma report from My Green Lab highlights the direct importance of miniaturized workflows for separation scientists in designing, validating, and scaling analytical methods.
This shift is driven by emissions data. The report shows that Scope 3 emissions dominate the carbon footprints of biotech and pharma companies, accounting for approximately 75% of public companies' carbon footprints and nearly 90% of private companies' carbon footprints. Crucially, "Purchased Goods and Services" account for approximately 80% of this Scope 3 impact. This category includes materials—solvents, columns, consumables, reagents, instruments, packaging, and freight—which separation scientists regularly specify.
When Scope 3 emissions become the primary concern, analytical method choices are no longer purely technical; they become structural levers for corporate decarbonization.
Miniaturization Lowers Impact Per Analysis—But Changes Behavior
James Connelly, CEO of My Green Lab and a contributing author of the report, sees method miniaturization as a critical—but nuanced—lever for reducing emissions in analytical science.
“The reality of automation and miniaturization, and the implementation of tools like AI and machine learning, is that each individual test has a lower impact,” explains Connelly. However, he adds that it can lead to significantly more testing. While miniaturization reduces per-analysis emissions, it may increase overall testing volume as automation and data-driven workflows expand.
“I don’t think our position at My Green Lab—or any environmental organization—should be that we pursue less testing,” advises Connelly. “There are huge benefits to being able to do more tests at volume and generate more data that we can use with AI and machine learning to understand and evaluate results.” He emphasizes that sustainability gains arise from reducing material and carbon intensity per unit of output rather than from constraining scientific output.
For separation scientists, this distinction matters. Miniaturized liquid chromatography (LC), microflow mass spectrometry (MS), and reduced-scale sample preparation reduce solvent and consumable use per run. Even as throughput increases, material intensity per data point continues to decline. That aligns with decarbonization goals without constraining scientific output.
Where Separation Science Hits Scope 3 Directly
The Carbon Impact Report makes one macro point especially relevant to chromatography labs. Scope 3 emissions dominate, and purchased goods dominate Scope 3. Analytical methods strongly influence how much of those goods are consumed during routine laboratory operations.
Smaller-scale separations reduce multiple Scope 3 contributors at once:
- Solvents and chemicals: Lower flow rates and smaller injection volumes cut upstream emissions from chemical manufacturing, packaging, and hazardous transport.
- Consumables and plastics: Reduced sample-preparation volumes mean fewer tubes, filters, vials, and tips entering regulated-waste streams.
- Freight and logistics: Lowering material shipments reduces transportation-related emissions, including those associated with cold-chain logistics for certain reagents.
“Miniaturization, dematerialization, and microfluidics are important technologies that allow testing at lower carbon and material impact,” notes Connelly, underscoring their direct role in reducing Scope 3 emissions tied to solvents, consumables, and logistics.
For labs already under pressure to manage solvent costs and waste disposal, the climate benefit aligns with operational incentives.
Capital Goods and Method Scale
The report also highlights another often-overlooked Scope 3 category: capital goods, which account for approximately 10% of Scope 3 emissions. For separation scientists, this includes LC systems, pumps, detectors, mass spectrometers, and columns.
Miniaturized methods extend the useful life of this equipment. Lower flow rates reduce wear on pumps and seals. Reduced solvent exposure lowers contamination and fouling. Columns operated under gentler conditions often last longer and require fewer replacements.
That longevity matters because embodied emissions—those associated with manufacturing, shipping, and installing instruments—fall outside the lab’s Scope 1 and 2 footprint but are significant in Scope 3 accounting.
From a sustainability standpoint, every extra year of productive instrument and column life avoids a new wave of upstream emissions.
Validation, Regulation, and Changing Methods Safely
Pharma, biotech, and regulated food labs face a real barrier. Validated analytical methods resist change. “Rather than providing prescriptive actions for what labs need to do, it’s about educating scientists upstream,” explains Connelly. “When they design analytical methodologies, they think about sustainability from the outset.” He adds that embedding sustainability during method design allows lower-impact workflows to move through validation as the default rather than as a retrofit.
This upstream approach shifts sustainability from a retrofit problem to a design criterion. Methods developed with reduced volumes and materials can be validated as the default option rather than an exception.
“There’s increasing willingness from regulators to consider new, innovative approaches. The industry is more open to change now than it ever was before.” Connelly notes that this regulatory openness creates a window for miniaturized methods to become standard practice.
For separation scientists involved in method development, this creates an opening. Designing miniaturized workflows early reduces the need for disruptive post-approval changes later.
Supplier Pressure Reinforces Method Choices
Supplier programs accelerate this shift. The ACT Ecolabel and Converge initiatives evaluate products at the company, facility, and product level, including impact during use. That scoring directly rewards tools that enable reduced solvent and material consumption.
“Once you give a scorecard to a product in this industry, we’re all students—we want the best score,” remarks Connelly. “As soon as someone produces a result with less usage, other manufacturers won’t score as highly on the ACT label,” he adds, describing how transparent product scoring creates competitive pressure that accelerates adoption of lower-impact analytical tools.
For separation scientists, this means procurement and method design are converging. Instruments, columns, and consumables optimized for microflow LC, supercritical fluid chromatography (SFC), or reduced-scale workflows gain an advantage. Competing products must follow or fall behind.
“It creates a virtuous cycle where better, more efficient products drive peers to follow the same pathway, ultimately benefiting the whole industry,” advises Connelly, noting that this cycle aligns procurement decisions with method-level sustainability gains.
Decoupling Growth From Emissions
“We’re able to achieve revenue growth that’s decoupled from increasing carbon impact, and innovations like miniaturization and microfluidics are making that possible,” asserts Connelly, noting that analytical innovation enables industry growth without locking in proportional emissions increases.
For separation scientists, the implication is direct. Method choices influence corporate climate performance at scale. Miniaturization is no longer on the margins of efficiency discussions. It touches the largest emissions category in the industry.
The Message for Separation Scientists
The Carbon Impact Report makes the macro case. In a value chain driven largely by upstream materials and equipment, analytical methods directly shape how much solvent, consumables, and capital flow into the supply chain.
Miniaturized LC, microflow MS, SFC adoption, and reduced-volume sample preparation shrink solvent use, plastics, freight, and capital turnover. They lower emissions per analysis while supporting higher data density and advanced analytics.
For separation scientists in pharma, biotech, and food testing labs, the takeaway is clear. Method miniaturization is no longer just good chromatography. It is part of the industry’s decarbonization infrastructure—designed one method at a time.